^Planegg/Martinsried, Germany, April 30, 2026 – The Leo International Precision
Health AG (“LIPH” or “the company”, ticker symbol: LEOW), a
Holding company that is a global, integrated and AI-driven
Healthcare Ecosystem today announced its consolidated financial results for
published for the 2025 financial year. The year under review was a phase of
Changes in the company’s origins and development history
the structural, operational and strategic foundations for the
growth strategy was laid out.
HIGHLIGHTS 2025
* Successful listing in the General Standard of the Frankfurt Stock Exchange
through a reverse takeover of SPOBAG AG, making LIPH listed on the stock exchange
Precision health platform was established.
* Acquisition of six majority stakes in December 2025, which
operational basis for the integrated precision healthcare ecosystem
form a group; whose valuation is currently around 111 million euros.
* Strategic positioning as international and synergistic
Investment platform with a focus on AI-driven innovations
Healthcare in the areas of Healthcare Services, MedTech, HealthTech
and biotech.
“The 2025 financial year represents a decisive milestone in the
Development of our company. With the IPO and the acquisition
We have successfully laid the foundation for our first portfolio companies
our strategy to create a globally integrated, AI-driven healthcare
“To build an ecosystem,” explains Prof. Dr. Joshua Lo, CEO of LIPH
In the future, our focus will be on strategic portfolio expansion
operational integration and the realization of synergies, whereby the
strategic focus on AI-driven precision healthcare assets across the
The entire spectrum of healthcare services, medtech, healthtech and biotech lies.
This gives investors transparent access to rapidly growing companies
Asian and global healthcare markets and supports sustainable
long-term value creation for our shareholders.”
EARNINGS, ASSETS AND FINANCIAL POSITION
The group was incorporated on December 31, 2025 as part of the contribution of six
Portfolio companies formed as part of a capital increase in kind. Accordingly
There are no comparative figures for the previous year and the consolidated financial statements
primarily reflect the initial establishment of the group structure
and no ongoing operational business activity yet. Until the formation of the
Group at the end of the year, no consolidation was carried out in the 2025 financial year
operational activities carried out.
Asset and balance sheet structure
As of December 31, 2025, the balance sheet total amounted to EUR 198.8 million
predominantly consisted of long-term assets amounting to EUR 197.0 million
and the initial consolidation of the contributed portfolio companies
reflects. The asset structure is largely determined by intangible assets
Assets amounting to EUR 195.7 million, including in particular
Goodwill, technologies, contractual rights,
Recipes, software and customer relationships that are part of the
Purchase price allocations were identified and evaluated. This long term
aligned strategic assets form the basis for the
future operational development and value creation of the group.
Capital structure and financial position
As of the balance sheet date, the group reported equity of EUR 172.9 million
corresponds to a solid equity ratio of around 87%. The
Financial liabilities were at a moderate level and result in the
Mainly from bank loans, leasing liabilities and
Shareholder loans that were taken over during the initial consolidation. There
the group was only formed at the end of the year, arose in the financial year
No operational cash flow development in 2025; the financial situation is reflected in the
Essentially the initial financing structure of the consolidated
subsidiaries.
Liquidity and financing
As of December 31, 2025, the group had an orderly liquidity situation
with cash and cash equivalents amounting to EUR 0.4 million. The
Liquidity was provided through existing financing structures as well as the ongoing
financial support for the majority shareholder and chairman of the supervisory board,
Hsiao-Hsuan?Leo” Wang, supported, including a pledged
Shareholder loan in the amount of EUR 2.0 million as of the balance sheet date
was partially used. In addition, the majority shareholder
Capital injections of up to EUR12.0 million committed for the 2026 financial year,
a first tranche of which was already paid in March 2026. Based on the
Based on current liquidity planning, the Management Board assumes that the Group
can meet its payment obligations at any time; Notes on
There were no liquidity bottlenecks as of the reporting date.
FORECAST FOR THE 2026 FISCAL YEAR
LIPH expects to further expand its network in the 2026 financial year
Investment platform that is supported both by operational integration and by
a selective expansion of the portfolio is promoted.
Sales volume
For the 2026 financial year, the group expects consolidated sales revenue in
a range of EUR 11 million to EUR 15 million. The forecast reflects this
expected development of the operating segments as well as the ongoing
Integration process of the portfolio companies. The outlook is based on
cautious and well-informed assumptions about organic business development
and takes into account possible fluctuations in demand as well as exchange rate effects and
the current level of integration of the portfolio companies.
EBITDA
For the 2026 financial year, the group expects a consolidated EBITDA
Earnings (loss) in a range of EUR -4 million to EUR -6 million. The
operational development should improve gradually, supported by
Economies of scale, increasing utilization of existing capacities and the
ongoing realization of synergies within the group. That expected
negative EBITDA reflects, in particular, continued necessary investments in the
Development of the platform structure, integration measures and central administration
and control functions.
Liquidity outlook
Based on the current financial planning, the Management Board assumes that
existing liquidity is sufficient to continue ongoing business operations until the end
to finance the 2026 financial year.
About Leo International Precision Health AG
Leo International Precision Health AG (?LIPH”, ticker symbol: LEOW) is one
Holding company that is Europe’s first integrated AI-powered
Health ecosystem builds. With a strategic focus on AI-driven
Precision Health companies in the areas of Healthcare Services, MedTech,
LIPH offers investors access to expanding healthtech and biotech
Asian and global healthcare and life sciences market. Through
LIPH integrates optimization and synergies between the investments
Technology, data and operations to deliver medical outcomes and the
Accelerate portfolio performance.
Further information can be found on the company website
(http://www.liphag.com).
Forward-Looking Statements
This press release may contain forward-looking statements and information
which are based on LIPH’s current expectations and certain assumptions
based. Various known and unknown risks, uncertainties and others
Factors may cause actual future results to differ
Financial situation, the company’s business development, product development
and the estimates made here differ significantly from those presented here
differ. These include known and unknown risks and uncertainties
among other things, research and development, the official
approval process, the timetable for actions by supervisory authorities and
other government agencies, clinical outcomes, changes in laws and
Regulations, product quality, patient safety, patent disputes,
contractual risks and dependencies on third parties. The Leo International
Precision Health AG assumes no obligation to provide future-oriented information
to update statements or in the event of developments that are required by the
expected deviations to be corrected. This document does not constitute an offer
for sale nor an invitation to make an offer to purchase or to
Subscription to LIPH securities. There will be no public offer
securities of LIPH, nor is there any intention to do so. This
Document and the information contained therein may not be distributed in the United States
States of America, Canada, Australia, Japan or other jurisdictions
be distributed in which such an offer or such an invitation is made
would be forbidden.
Contact: Investor Relations and Media Contact:
MC Services AG
Leo International Precision Health AG Pamela Keck, Katja Arnold, Kaja Skorka
Am Klopferspitz 19 [email protected] (mailto:LIPH@mc-
82152 Planegg / Martinsried services.eu)
[email protected] +49 (0)89- 210 228-0
°
